Alembic Limited has informed the Exchange regarding Appointment of Mr Udit Amin as Managing Director of the company w.e.f. October 01, 2025.
ALEMBICLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Limited reported its Q1 FY26 (quarter ended June 30, 2025) results alongside a key leadership change. Consolidated revenue from operations stood at ₹4,975 lakhs, slightly down from ₹5,078 lakhs in Q1 FY25, while consolidated net profit (after share of associate Alembic Pharmaceuticals) rose to ₹6,164 lakhs from ₹5,582 lakhs, with consolidated EPS at ₹2.40 vs ₹2.17. The API segment grew strongly (revenue up ~21% YoY to ₹1,295 lakhs), while the real estate segment declined modestly (₹3,680 lakhs vs ₹4,006 lakhs). On governance, the Board appointed Mr. Udit Amin (currently a Non-Executive Director) as Managing Director for 5 years effective October 1, 2025, and accepted the resignation of Mrs. Malika Amin as MD & CEO effective January 1, 2026 — she will continue as a Non-Executive Director. Mr. Udit Amin is the son of Chairman Mr. Chirayu Amin and outgoing MD Mrs. Malika Amin, indicating a planned promoter-family succession.
The results are broadly stable with growth driven by the API business and associate earnings. The transition signals continuity through promoter-family succession, which should provide stability but limits independent board renewal at the top.